OPKO Health (NASDAQ:OPK) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of OPKO Health (NASDAQ:OPK) from a strong sell rating to a hold rating in a report published on Saturday morning.

A number of other brokerages have also weighed in on OPK. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a research report on Tuesday, July 8th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th. Jefferies Financial Group restated a “hold” rating and set a $1.60 price objective (down previously from $2.00) on shares of OPKO Health in a report on Thursday. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday. Finally, Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $2.28.

OPKO Health Price Performance

OPK stock opened at $1.36 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company’s 50-day moving average is $1.46 and its 200-day moving average is $1.38. The stock has a market capitalization of $1.08 billion, a PE ratio of -5.44 and a beta of 1.50. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. The business had revenue of $151.67 million for the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm’s revenue for the quarter was down 12.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 EPS. Equities research analysts expect that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 675,000 shares of OPKO Health stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $891,000.00. Following the purchase, the chief executive officer directly owned 214,676,448 shares in the company, valued at $283,372,911.36. The trade was a 0.32% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 49.69% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in OPKO Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock valued at $48,970,000 after buying an additional 293,740 shares during the last quarter. Sculptor Capital LP bought a new position in shares of OPKO Health in the first quarter valued at approximately $21,111,000. Geode Capital Management LLC increased its position in shares of OPKO Health by 23.7% during the second quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock valued at $13,763,000 after acquiring an additional 1,995,633 shares during the last quarter. Millennium Management LLC increased its position in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after acquiring an additional 1,798,385 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in OPKO Health by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock worth $6,642,000 after acquiring an additional 161,394 shares during the period. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.